---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-026506"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-06-26T12:30:33+00:00"
generated_at: "2026-06-26T12:35:13.533052+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BridgeBio director Scott resigns at annual meeting; stockholders approve 2M share increase in stock plan

## Summary
- Dr. Randal W. Scott resigned as Class I director effective June 22, 2026, upon term completion, citing no disagreement.
- Stockholders approved amending 2021 Stock Option Plan to increase reserved shares by 2,000,000.
- Elected Class I directors: Momtazee, McCormick, Valantine; all received >129M votes for.
- Non-binding advisory vote on executive compensation approved (152.9M for); 1-year frequency endorsed.

## SEC filing metadata
- accession: 0001140361-26-026506
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-06-26T12:30:33+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/0001140361-26-026506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/ef20076710_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-026506
- JSON: https://secwatch.observer/filing/0001140361-26-026506.json
- Plain text: https://secwatch.observer/filing/0001140361-26-026506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.